Shots:

• Novo Nordisk to invest $117.4M in upgrading and expanding facilities at its production site in Kalundborg- Denmark
• The facilities currently develop diabetic therapies and will be rebuilt and expanded for the future production of these and the next generation of diabetic therapies. The projects are expected to be completed in 2022
• The investment in production facilities will strengthen its presence in Denmark and Kalundborg

Click here ­to­ read full press release/ article | Ref: Novo Nordisk | Image: New Age